Devonian Health Group Inc - Asset Resilience Ratio
Devonian Health Group Inc (GSD) has an Asset Resilience Ratio of 0.00% as of July 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Devonian Health Group Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Devonian Health Group Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Devonian Health Group Inc (GSD) total assets.
Liquid Assets Composition Over Time
This chart breaks down Devonian Health Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Devonian Health Group Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Devonian Health Group Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Devonian Health Group Inc Industry Peers by Asset Resilience Ratio
Compare Devonian Health Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Devonian Health Group Inc (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Devonian Health Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-07-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$19.18 Million ≈ $13.87 Million |
-- |
| 2022-07-31 | 23.16% | CA$5.00 Million ≈ $3.62 Million |
CA$21.59 Million ≈ $15.62 Million |
-- |
| 2021-07-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$14.61 Million ≈ $10.57 Million |
-- |
About Devonian Health Group Inc
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for At… Read more